TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq:TCRX), a clinical-stage biotech developing TCR-T cell therapies for cancer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026 at 11:30 a.m. ET.

A live webcast and 90-day replay will be available on TScan's investor relations website.

News Market Reaction – TCRX

-4.35%

1 alert

-4.35% Session close to close

$57.57M Market Cap

0.0x Rel. Volume

In the Jun 24 session, TCRX declined 4.35%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming conference visibility for TScan’s TCR-T pipeline on June 30. P...

Analysis

This announcement highlights upcoming conference visibility for TScan’s TCR-T pipeline on June 30. Prior events show mixed market responses; key risks remain clinical execution and funding needs, while investors may watch for any new data or strategic updates from the fireside chat.

Key Figures

Conference date: June 30, 2026 Fireside chat time: 11:30 a.m. Eastern Time Webcast replay duration: 90 days +1 more

4 metrics

Conference date June 30, 2026 H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Fireside chat time 11:30 a.m. Eastern Time Scheduled webcast start time

Webcast replay duration 90 days Archived replay availability on company website

Conference edition 4th Annual H.C. Wainwright Cell Therapy Virtual Conference

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	Clinical data update	Positive	-5.5%	Positive Cohort C ALLOHA Phase 1 data for TSC-101 in heme malignancies.
Jun 03	Manufacturing agreement	Neutral	-0.8%	Agreement with Cellares to evaluate automated TSC-101 manufacturing.
May 06	Earnings and update	Neutral	+3.3%	Q1 2026 financials and cash runway into second half of 2027.
Apr 27	Conference presentation	Neutral	-3.8%	ASGCT poster on CD45-targeted TCR-T therapies announcement.
Apr 08	Conference participation	Neutral	-0.9%	Needham Virtual Healthcare Conference fireside chat participation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Conference and corporate news have typically seen modest, generally aligned moves, while a recent positive clinical update drew a notable negative divergence.

Key Terms

t cell receptor, tcr-t

2 terms

t cell receptor medical

"focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies"

A T cell receptor is a protein sensor on the surface of certain immune cells that recognizes small pieces of foreign or abnormal material, like fragments of a virus or a cancer cell, and helps trigger an immune response. Investors care because therapies and diagnostics that target or use these receptors act like reprogramming a security scanner to find specific threats, so success or failure in developing safe, effective T cell receptor–based drugs or tests can strongly affect a biotech company's value.

tcr-t medical

"T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients"

TCR‑T is a type of engineered cell therapy where a patient’s T cells are reprogrammed to carry specific T‑cell receptors that recognize fragments of disease proteins presented on the surface of cells. Think of it as giving immune cells a custom key to find and attack cells displaying a particular molecular “badge.” For investors, TCR‑T represents a high‑precision, potentially powerful treatment approach with significant commercial upside but also complex manufacturing, regulatory hurdles and safety risks that can affect development timelines and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 4^th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026 at 11:30 a.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
        
About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company is also in early stages of developing methods for in vivo engineering to treat solid tumors. In addition, the Company is applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.

Investor and Media Contact

Caileigh Dougherty
857-399-9890
ir@tscan.com

FAQ

When will TScan Therapeutics (TCRX) present at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference?

TScan Therapeutics will participate in a fireside chat on June 30, 2026 at 11:30 a.m. Eastern Time. According to the company, this session is part of the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

How can investors access the TScan Therapeutics (TCRX) webcast for the June 30, 2026 conference?

Investors can access the live webcast on the Events and Presentations section of TScan’s investor relations website at ir.tscan.com. According to the company, this webcast will cover its fireside chat at the conference.

Will a replay of the TScan Therapeutics (TCRX) H.C. Wainwright conference webcast be available?

Yes, an archived replay of the webcast will be available on TScan’s website for 90 days. According to the company, investors can revisit the June 30, 2026 fireside chat during this period.

What type of event is TScan Therapeutics (TCRX) joining at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference?

TScan Therapeutics is joining a fireside chat session at the conference. According to the company, this event will be webcast live, allowing investors and stakeholders to listen remotely.

Where is information about TScan Therapeutics (TCRX) events and presentations, including the June 30, 2026 conference, available?

Information about TScan Therapeutics events is available in the Events and Presentations section of its investor website at ir.tscan.com. According to the company, this includes access to the June 30, 2026 fireside chat webcast.